Next-Gen Antibody Therapeutics Market to Reach $22.88 Billion by 2033

The next-generation antibody therapeutics market is expected to expand significantly, reaching $22.88 billion by 2033, as announced in a press release by DataM Intelligence. This growth is attributed to breakthroughs in oncology and the integration of AI in drug design.

In 2024, the market size was $9.09 billion, up from $8.28 billion in 2023, with a projected compound annual growth rate (CAGR) of 10.9% from 2025 to 2033. The market's expansion is driven by the adoption of advanced antibody technologies, including antibody-drug conjugates (ADCs), bispecific antibodies, and Fc-engineered antibodies, which are enhancing precision medicine and expanding treatment options.

Oncology remains the dominant therapeutic area, contributing nearly 60% of the market revenue in 2024. The U.S. leads the market with a valuation of approximately $4.7 billion in 2024, supported by a robust biopharma ecosystem and favorable regulatory pathways. Japan is also emerging as a significant player, with strategic alliances and regulatory reforms accelerating the approval of biologics.

DataM Intelligence highlights that the market's future will be shaped by clinical breakthroughs, faster regulatory pathways, and the fusion of digital technologies with drug discovery, offering substantial opportunities for industry stakeholders.